CD19-Targeted Immunotherapy Attenuates Vessel Wall Inflammation

被引：4
|
作者：
Derlin, Thorsten [1 ]
Koenecke, Christian [1 ]
Schultze-Florey, Christian [1 ]
Ganser, Arnold [1 ]
Bengel, Frank M. [1 ]
机构：
[1] Hannover Med Sch, Dept Nucl Med, Carl Neuberg Str 1, D-30625 Hannover, Germany
来源：
JACC-CARDIOVASCULAR IMAGING | 2021年 / 14卷 / 09期
关键词：
D O I：
10.1016/j.jcmg.2021.02.025
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1864 / 1866
页数：3
相关论文
共 50 条
  • [1] Understanding Outcomes of CD19-Targeted CAR T Cell Immunotherapy
    Turtle, Cameron J.
    BLOOD, 2017, 130
  • [2] CD22-TARGETED IMMUNOTHERAPY FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-ALL WHO PREVIOUSLY EXPOSED TO CD19-TARGETED IMMUNOTHERAPY
    Zhang, Mingming
    Hu, Yongxian
    Lu, Peihua
    Huang, Liang
    Fu, Shan
    Feng, Jingjing
    Hong, Ruimin
    Chang, Alex H.
    Huang, He
    BONE MARROW TRANSPLANTATION, 2024, 59 : 146 - 146
  • [3] Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy
    Kambhampati, Swetha
    Fakhri, Bita
    Sheng, Ying
    Huang, Chiung-Yu
    Byslma, Sophia
    Natsuhara, Kelsey
    Biswas, Dhruba
    Lo, Mimi
    Ai, Weiyun Z.
    Kaplan, Lawrence D.
    Martin, Thomas, III
    Wolf, Jeffrey L.
    Shah, Nina
    Andreadis, Charalambos
    Wong, Sandy W.
    BLOOD, 2020, 136
  • [4] How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy
    Aldoss, Ibrahim
    Forman, Stephen J.
    BLOOD, 2020, 135 (11) : 804 - 813
  • [5] Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review
    Locatelli, Franco
    Shah, Bijal
    Thomas, Tracy
    Velasco, Kelly
    Adedokun, Babatunde
    Aldoss, Ibrahim
    Gore, Lia
    Hoelzer, Dieter
    Bassan, Renato
    Park, Jae H.
    Boissel, Nicolas
    Kantarjian, Hagop
    LEUKEMIA & LYMPHOMA, 2023, 64 (10) : 1615 - 1633
  • [6] Recent developments in CD19-targeted therapies for follicular lymphoma
    Saha, Aditi
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (10) : 1049 - 1055
  • [7] CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
    Fry, Terry J.
    Shah, Nirali N.
    Orentas, Rimas J.
    Stetler-Stevenson, Maryalice
    Yuan, Constance M.
    Ramakrishna, Sneha
    Wolters, Pamela
    Martin, Staci
    Delbrook, Cindy
    Yates, Bonnie
    Shalabi, Haneen
    Fountaine, Thomas J.
    Shern, Jack F.
    Majzner, Robbie G.
    Stroncek, David F.
    Sabatino, Marianna
    Feng, Yang
    Dimitrov, Dimiter S.
    Zhang, Ling
    Sang Nguyen
    Qin, Haiying
    Dropulic, Boro
    Lee, Daniel W.
    Mackall, Crystal L.
    NATURE MEDICINE, 2018, 24 (01) : 20 - +
  • [8] Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
    Maher, John
    CURRENT GENE THERAPY, 2014, 14 (01) : 35 - 43
  • [9] Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy
    Hill, Joshua A.
    Li, Daniel
    Hay, Kevin A.
    Green, Margaret L.
    Cherian, Sindhu
    Chen, Xueyan
    Riddell, Stanley R.
    Maloney, David G.
    Boeckh, Michael
    Turtle, Cameron J.
    BLOOD, 2018, 131 (01) : 121 - 130
  • [10] Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy
    Gao, Zhilin
    Lian, Yu
    Ti, Juanjuan
    Ren, Ruirui
    Ma, Liangming
    ANTI-CANCER DRUGS, 2023, 34 (04) : 551 - 557
12345